Genmab — November 2020
-
Det når vi nok ikke i dag...på trods af Mcjean´s proferi.
-
profeti
-
NBI i +
-
Given that it is 'happy mRNA day', this is another Genmab abstract, where they sought to characterize protein and mRNA biomarkers in the tumor and stromal microenvironment
https://jitc.bmj.com/content/8/Suppl_3/A255 -
Fååk - bunch of losers;-)
-
We are
all losers...sometime..:-) -
Men stadig NBI +0,69% pt.
-
Følg NBI her. Der er ikke storudsalg af Pharma i US. https://indexes.nasdaqomx.com/Index/Overview/NBI
-
Shoot me, hvis jeg har overset det tidligere, men abstract for gen1046 https://jitc.bmj.com/content/8/Suppl_3/A437 angiver, at der faktisk bliver præsenteret opdaterede data, og at 65,6% (40/61) pts opnåede stable disease eller partial response. Fordelt over både triple-negative breast cancer, ovarian cancer, and immune checkpoint inhibitor (ICI)–pretreat
ed NSCLC -
E L ..One more?
-
Genmab presented dose escalation data for its DuoBody-PD-L1x4-1BB in 61 patients with advanced solid tumours at SITC today with six months of follow up. Early data is encouraging with an 11-33% ORR across TNBC https://twitter.com/semodough/status/1325984229063192576?s=21
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind